...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Management and Research >Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
【24h】

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases

机译：Bevacizumab与Pemetrexed和铂族相结合，显着改善了晚期腺癌NSCLC和脑转移患者的临床结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The study aims to evaluate the clinical efficacy and safety of bevacizumab in combination with the first-line pemetrexed-platinum (PP) in patients with advanced adenocarcinoma non-small-cell lung cancer (NSCLC) and brain metastases. Methods: The clinical data of patients with adenocarcinoma NSCLC and symptomatic or asymptomatic brain metastases were collected in our study. The basic chemotherapy regimen was pemetrexed-platinum (PP). According to whether combined with bevacizumab (B) or not, all enrolled patients were assigned to the B+PP group or the PP alone group. Results: A total of 71 patients were enrolled in the current study. Twenty-six patients were allocated to the B+PP group and 45 were allocated to the PP group. Overall response rates (ORRs), disease control rates (DCRs) of the thoracic tumors and intracranial metastases and overall survival (OS) were not significantly different between the 2 groups. However, progression-free survival (PFS) and intracranial PFS (iPFS) were significantly prolonged in the B+PP group compared with the PP group. The median PFS was 9.2 and 8.2 months, and the 1-year PFS rates were 47.1% and 15.9%, respectively, in the 2 groups ( P =0.029). And, the median iPFS were 24.3 and 10.9 months, and the 1-year iPFS rates were 80.1% and 40.1%, respectively, in the 2 groups ( P =0.008). Univariate and multivariate analyses suggested that maintenance therapy and bevacizumab therapy were independent favorable prognostic factors of PFS and iPFS. Conclusion: The addition of bevacizumab to the first-line pemetrexed and platinum significantly improved clinical outcomes of patients with advanced adenocarcinoma NSCLC and brain metastases.
机译：背景：该研究旨在评估贝伐单抗与先进腺癌非小细胞肺癌（NSCLC）和脑转移患者患者组合贝伐单抗的临床疗效和安全性。方法：在我们的研究中收集了腺癌和症状或症状或无症状脑转移患者的临床资料。基本化疗方案是磷酸戊酰胺（PP）。根据与Bevacizumab（b）组合，所有注册的患者是否已分配给B + PP组或单独的PP。结果：目前共有71名患者参加了71名患者。将二十六名患者分配给B + PP组，将45个分配给PP组。胸部肿瘤和颅内转移的总反应率（ORRS），疾病控制率（DCR）和总存活（OS）在2组之间没有显着差异。然而，与PP组相比，B + PP组在B + PP组中显着延长无进展存活（PFS）和颅内PFS（IPF）。中位数PFS为9.2和8.2个月，在2组中，1年的PFS率分别为47.1％和15.9％（P = 0.029）。并且，中位数IPFS为24.3和10.9个月，在2组中，1年的IPFS率分别为80.1％和40.1％（P = 0.008）。单变量和多变量分析表明，维持治疗和Bevacizumab治疗是PFS和IPF的独立良好的预后因素。结论：将贝伐单抗添加到一线磷酸盐和铂显着改善了晚期腺癌NSCLC和脑转移患者的临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号